19800 MacArthur Boulevard, Suite 300 Irvine, California 92612
+1.778.288.1389

The Worldwide CSi-EDP Crypto-ECO-System

Biggest Crypto offering ever!

Our Worldwide CSi-EDP Corporate Presence and our CSi-EDP Corporate Culture is focused on Education, Job Creation, and Cannabinoid Drug Development. Successful GROWTH will “Once again” become the main focus and continue to Drive the CSi-EDP Success forward. Cannabis Science, Inc. is a patient-oriented company dedicated to meeting the needs of the community with products based on cannabinoid science, as well as being an advocate for patient rights throughout the world.

First token sales ends in:
Days
Hours
Minutes
Seconds


Contract address
0xa403da25b0f3c5f580638a5dd060d126ad808cbb
Token name:
Cannabis Science Coin
Ticker Symbol:
$CSI
Maximum supply:
2,000,000,000
Max Buy
1.7500% (35,000,000)
25 millions Token sale
10 millions Hard Cap

etherium
bitcoin
visa
mastercard
The first public CSi-EDP Cannabis Science Coin $CSI Launch has started, will end in:
Days
Hours
Minutes
Seconds
Your crypto!
Your life!

Contract address
0xa403da25b0f3c5f580638a5dd060d126ad808cbb
Token name:
Cannabis Science Coin
Ticker Symbol:
$CSI
Maximum supply:
2,000,000,000
Max Buy
1.7500% (35,000,000)

1st stage ends in:
Days
Hours
Minutes
Seconds
Your crypto!
Your life!


Contract address
0xa403da25b0f3c5f580638a5dd060d126ad808cbb
Token name:
Cannabis Science Coin
Ticker Symbol:
$CSI
Maximum supply:
2,000,000,000
Max Buy
1.7500% (35,000,000)

Read our
White Paper
More Participants
Fluctuate $CSI
Cannabis Science Coin $CSI
Why choosing us

We believe we have at least (5) potential FDA Critical Ailment Drug Development Target indications, these are considered, “potential Billion Dollar BLOCKBUSTER Drugs” targeting several Critical Ailments, potential FDA Drug Development of Target indications is our focus here. Our Award-winning cannabinoid drug development “research success” is clearly evidenced by our ground-breaking Harvard Award winning research and the peer reviewed Success in Frontiers on Oncology.

peer reviewed Success in Frontiers on Oncology.

Then you add the CBN Patent for Neurological Conditions, to the extensive Successful cannabinoid drug development Product Pipeline targeting the FDA, State by State, and Industrial Hemp, brings you to the conclusion that based on its Award-winning clinical and pre-clinical research, product development track record, this Company will get the Job Done. This is what it is all about, just get one BLOCKBUSTER Critical Ailment Drug on the market NOW so you can affect/make your positive change to the World we all live in.

CBN Patent for Neurological Conditions

CSi has access to over 3 000 acres for contract in CA and NV for our CSi EDP’s In Stockton, CA, CSi had a 250-acre program underway with Free Spirit Organics (Native American Corporation). Our initial, 25-acre harvest was illegally seized by the local government and this matter is currently being litigated
Our team of legal experts expect CSi to prevail in this case, we will hire more lawyers to complete asap. 77 million is the filed number they stole in our inventory!

77 million is the filed number they stole in our inventory!

Support countries
75%
Operators
44%
Producers
62%
How artificial intelligence & block chain revolutionize the world of online marketplaces
Our Tokens
What is Cannabis Science Coin $CSI?
Cannabis Science Coin $CSI is a token, Binance Coin based on the Ethereum blockchain technology. It is the core asset of the new Cannabis Science Coin $CSI Marketplace.

Without blockchain fluctuations

No transaction
fees

Protects
the identity

Instant
operations

Cannabis Science Coin $CSI

Cannabis Science, Inc is about to launch vibrant and independent conglomerate SPAC Group economies with their communities powered by the Ethereum blockchain. FDA, product pipeline plus our patents and more, the numbers are absolutely MASSIVE! Interested investors can buy into the offering and receive our cryptocurrency token. Check us out here: https://cannabisscience.com

At least 5 Billion Dollar BLOCKBUSTER Target Drugs.
This is what it is all about, just to get one.

CSi Utility Coin Financial Structure:
Each vested CSi Utility Coin Project will be assigned a CSi-EDP Partner to Grow each CSi-EDP Opportunity! A 25% CSi Utility Coin Profit structure built into ALL vested projects-launched through the CSi-EDP! The CSi Utility Coin will have a direct financial attachment to ALL-vested CSi-EDP Projects, 25% profit sharing. Each vested CSi-EDP Project will assign 25% in PROFITS to the CSi Utility Coin!

EVERYONE BENEFITS !!!
Includes All vested CSi-EDP Projects assigned after August 1, 2021

Earn staking rewards just by holding $CSI token!

$CSI is an experimental community-driven token, which goal is to set new records for market cap and media mentions. It’s a low supply community coin, which is deflationary over time. Each token locked or burned is designed to ensure constant price increase.

In order to make CRI token distribution process efficient, the CRI price is linked to Polygon MATIC

Fund distribution
  • 35 millions Token
  • 10 millions Hard Cap
  • 25 millions Token Sale
Proposed distribution
  • 45% Distributed to Community
  • 25% Reserved Funding
  • 9% Founders and Team
  • 3% Advisors
  • 2% “Bounty” campaign
Roadmap
Our Strategy and Project Plan

Our Worldwide Corporate Presence and our Corporate Culture will “Once again” become the main focus.

Our FDA Drug Development Targets are second to none.

We believe we have at least (5) potential FDA Critical Ailment Drug Development Target indications, these are considered, “potential Billion Dollar BLOCKBUSTER Drugs” targeting several Critical Ailments, potential FDA Drug Development of Target indications is our focus here.

Our Award-winning cannabinoid drug development “research success” is clearly evidenced by our ground-breaking Harvard Award winning research and the peer reviewed Success in Frontiers on Oncology.

Clear peer reviewed Success in Frontiers on Oncology

Then you add the CBN Patent for Neurological Conditions, to the extensive Successful cannabinoid drug development Product Pipeline, targeting the FDA, State by State, and Industrial Hemp, brings you to the conclusion that based on its Award-winning clinical and pre-clinical research, product development track record, this Company will get the Job Done.

CBN Patent for Neurological Conditions

This is what it is all about, just get one BLOCKBUSTER Critical Ailment Drug on the market NOW so you can affect/make your positive change to the World we all live in.

At least 5 billion Dollar BLOCKBUSTER Target Drugs. This is what it is all about, just to get one.

This is done through our Corporate packages, Product Brochures, FDA BLOCKBUSTER DRUG targets, CBN Patent products, ALL our State-by-State Projects, tracking and negotiating software. This is all for our Growth and Reporting as we Grow.

CSi has access to over 3 000 acres for contract in CA and NV for our CSi EDP’s In Stockton, CA, CSi had a 250-acre program underway with Free Spirit Organics (Native American Corporation).

Our initial, 25-acre harvest was illegally seized by the local government and this matter is currently being litigated
Our team of legal experts expect CSi to prevail in this case, we will hire more lawyers to complete asap. 77 million is the filed number they stole in our inventory!

77 million is the filed number they stole In our inventory!

Strategic Plan
Cannabis Science, Inc … (is a U S company specializing in the development of cannabinoid-based medicines to target critical ailments and improve palliative care, including various cancers, chronic pain, and neurological disorders, along with HIV/AIDS, COPD, PTSD, and many others. Cannabis Science is expanding its CSi EDP footprint Internationally and intends to do so much faster through its unique CSi Utility Coin offering. Expanding and implementing Worldwide economic development through its Harvard Award Winning, Powerful CSi EDP, focused on Education, Job creation, and Cannabinoid Drug Development.

CSi UTILITY COIN Overview

YOUR Billion Dollar Crypto Currency Opportunity, BLOCKBUSTER Drug Development, CSi.
Your CSi UTILITY COIN investments will directly impact your CSi EDP footprint and will directly benefit a wide variety of communities worldwide, financially Direct impacts include more jobs from educating, creating jobs through CSI EDP Entrepreneurs. Programs, to growing and cultivating medical cannabis and industrial hemp. Creating new industry and new products, to the manufacturing and distribution of cannabinoid-based medicines to patients covering the complete medical spectrum, from the FDA targeting critical ailments, to palliative care Cosmo/Nutraceuticals, State by State, and Industrial Hemp products and research.

Tactical Plan
CSi corporate vision is to create a patient-oriented, vertically-integrated, entrepreneurial growth organization that controls the development of its medicines through its CSi-EDP for community access and advantages from mass multiple industry job creation to farm-to-bedside medicines in three market segments: Federal (FDA-approved drugs), State-by-State, and Industrial Hemp.

In an Aggressive Entrepreneurial expansion each Approved CSi-Partner Country, State, City, or Community will receive a full CSi-EDP tactical plan for their Partner plan over the next 2-3 years depending on the budget and emergency circumstances. The CSi-EDP will include the development of partnerships with State and Local government agencies, as appropriate, and various local industry to create jobs and expand business:

• Establish research, development, and testing operations
• Establish cannabis and hemp cultivation operations
• Establish extraction, manufacturing, production, and distribution operations
• With a University partner, establish research, education, and training activities
• Open CSi pharmacies and Medical centers
• Support the development of complementary businesses, including security, technology, media, retail, etc.
• Collaborate with local-based organizations, including the Chamber of Commerce and its member companies.

Operational Plan
The CSi-EDP mission is to positively affect the needs of distressed communities, cities, and countries worldwide
through simple economic stimulation through our Harvard Award winning economic development programs.

Our FLAGSHIP OPERATIONS:
(1) Our FDA Drug Development Targets are second to none. We believe as evidenced by the groundbreaking Harvard Award winning research and clear peer reviewed Success in Frontiers on Oncology and the CBN Patent for Neurological Conditions, to the extensive Successful cannabinoid Product Pipeline covering the FDA, State by State, and Industrial Hemp.
At least (5) Billion Dollar BLOCKBUSTER Target Drugs. This is what it is all about, just to get one.

(2) CSi has access to over 3,000 acres for contract in CA and NV for our CSi-EDP’s. In Stockton,CA, CSi had a 250-acre program underway with Free Spirit Organics (FSO) Native American Corporation (NAC). Our initial, 25-acre harvest was illegally seized by the local government and this matter is currently being litigated. Our team of legal experts expect CSi to prevail in this case, we will hire more lawyers to complete asap.

(3) In Partnership with CSi-EDP, American States University, RCDU, AHU, (Attached ASU Report) and many Universities will provide Hybrid Online and on the job training at all levels, as each community requires.

• Research Collaborations: CSi will leverage our previous research collaborations, including with the Dana- Farber Cancer Institute at Harvard Medical School and Stellenbosch University, the oldest University in South Africa. In the laboratory, CBIS and our research collaborators have killed stage 4 cancer and have made several important findings. With Dana-Farber, CBIS has published two peer-reviewed articles in the online journal, Frontiers in Oncology. We will begin final target indication preparations for our initial FDA drug development program.

• Pharmacies & Medical Centers: Previously, CSi opened two pharmacies in California and plans to open several medical centers to engage directly with patients, as well as to support our observational and clinical studies for drug development. These pharmacies are important History as these distribution centers and the business model for these pharmacies was developed for franchising. We will launch the full CSi franchising line of pharmacies, products, and grow.

• Technological Innovations: CSi’ technological innovations – iCannabinoid, iCannabinoid Marketplace – provide us with unique platforms to engage with patients and stakeholders, facilitate real-time industry transactions that are tracked and controlled, and to access financing for our initiatives.

Financial Goals and Objectives, ADVANCING OUR SUCCESS NOW !!!
(1) CSi-EDP presentation from the 2019 Global Health Catalyst (GHC) Summit at Harvard Medical School;
(2) CSi-EDP presentation from the 2018 European GHC Summit at Heidelberg University in Germany;
(3) Invitation Mr. Raymond C. Dabney recipient 2018 GHC Industry Leader Award at Harvard Medical School;
(4) Multi-Million Dollar CSi-EDP collaboration, industrial hemp research projects with FSO NAC.
(5) CBN Patent, and the potential BLOCKBUSTER Billion Dollar Product Pipeline.

• CSi-EDP Corporate Overview, Team History
• CSi-EDP American States University Partnership Outlined (ALL PREVIOUS DD WORK TO ADVANCE)
• CSi-EDP African CFA Drug and Economic Development (ALL PREVIOUS DD WORK TO ADVANCE)
• CSi-EDP Industrial iHemp Trading current and planned initiatives
• Cannabis Science Product Development Pipeline 3x (ALL PREVIOUS DD WORK TO ADVANCE)
• CSi-EDP Medical Consortium. Medical Centers, Pharmacies (ALL PREVIOUS DD WORK TO ADVANCE)
• CSi-EDP K-12, University, and Entrepreneurial job creation level education.
• The Hempery Product Development Pipeline (ALL PREVIOUS DD WORK TO ADVANCE)
• The HempTasty Product Development Pipeline (ALL PREVIOUS DD WORK TO ADVANCE)
• CSi-EDP and the Hemp Industrial Revolution.

CSi-EDP will use the CSi Utility Coin for several of its transaction-based products and services.
Each product and or service provided or released will become a part of the CSi Utility Coin eco system, multiplying the Coin value and reach!

Financial Goals and Objectives
• The CSi EDP will be the main FUEL for the CSi Utility COIN. The main Goal of the CSi EDP is to Educate and create Jobs in any distressed community!

CSi Utility Coin Financial Structure
Each vested CSi Utility Coin Project will be assigned a CSi-EDP Partner to Grow each CSi-EDP Opportunity!
A 25% CSi Utility Coin Profit structure built into ALL vested projects launched through the CSi-EDP!
The CSi Utility Coin will have a direct financial attachment to ALL vested CSi-EDP Projects, 25% profit sharing.
Each vested CSi-EDP Project will assign 25% in PROFITS to the CSi Utility Coin!

EVERYONE BENEFITS !!!
Includes All vested CSi-EDP Projects assigned after August 1, 2021

Earn staking rewards just by holding $CSI token!

$CSI is an experimental community-driven token, which goal is to set new records for market cap and media mentions.
It’s a low supply community coin, which is deflationary over time.
Each token locked or burned is designed to ensure constant price increase.

Contract address
0xa403da25b0f3c5f580638a5dd060d126ad808cbb
Token name:
Cannabis Science Coin
Ticker Symbol:
$CSI
Maximum supply:
2,000,000,000
Max Buy
1.7500% (35,000,000)
Cannabis Science Coin $CSI
Partners & Supporters
We Collaborate Only With The Best

Cannabis Science Coins $CSI

Frequently Questions

We are NOT some technology or gaming start-up firm. We are the real Cannabis Science Inc. McCoy Coin! $SCI is powered by the Ethereum blockchain.

Yes we are! Check out about us on: https://www.cannabisscience.com

This website is pure about our coin, Then you add the CBN Patent for Neurological Conditions, to the extensive Successful cannabinoid drug development Product Pipeline targeting the FDA, State by State, and Industrial Hemp, brings you to the conclusion that based on its Award-winning clinical and pre-clinical research, product development track record, this Company will get the Job Done. This is what it is all about, just get one BLOCKBUSTER Critical Ailment Drug on the market NOW so you can affect/make your positive change to the World we all live in.

We believe we have at least (5) potential FDA Critical Ailment Drug Development Target indications, these are considered, “potential Billion Dollar BLOCKBUSTER Drugs” targeting several Critical Ailments, potential FDA Drug Development of Target indications is our focus here. Our Award-winning cannabinoid drug development “research success” is clearly evidenced by our ground-breaking Harvard Award winning research and the peer reviewed Success in Frontiers on Oncology.

Cannabis Science strives to be a leader in cannabinoid medicine, and we are seeking those who share our vision, want to help us reach our goals, and have the experience to be the leaders of tomorrow. As we expand nationally and globally, we require individuals with worldly experience, a desire to help those in need, and the drive to change the world. If you have what it takes, we welcome you to apply for available positions in the various aspects of our company.
https://www.cannabisscience.com/about-us/careers-corporate-culture

CORPORATE OVERVIEW.


Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.

Cannabis use has an extensive history dating back thousands of years, and currently, there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting-edge ideas flourish and translate into evidence-based solutions.

We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first-class cannabinoid pharmaceuticals to those critically in need of new treatments for life-threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are cGMP compliant, surpassing high quality standard industrial and food processing requirements.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders.

Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.

In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled “Composition for the Treatment of Neurobehavioral Disorders” (CS-NEURO-1). The subject of the patent is the development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders.


BASIS & PHILOSOPHY.


Cannabis plants have an extensive history of medical and agricultural use dating back thousands of years. To date, hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

SOME KEY PHYTOCANNABINOIDS:

  • tetrahydrocannabinol (THC)
  • cannabidiol (CBD)
  • cannabigerol (CBG)
  • cannabichromene (CBC)
  • cannabinol (CBN)

These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.

Cannabis Science is developing novel cannabis-based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting-edge cancer treatments.

The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.

These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.

As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire “seed to sale” process with a focus on biopharmaceutical development.

Cannabis Science is one of the longest standing companies in the cannabis business.

We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.

THE SCIENCE OF CANNABINOIDS.


Cannabinoids have an extensive history dating back thousands of years, and currently, there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

Some applications of cannabinoids have been well established in peer-reviewed literature such as alleviating nausea and stimulating the appetite for people with AIDS and Cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Some current uses are poorly understood, such as its perceived effectiveness in alleviating certain autoimmune disorders, such as Crohn’s Disease.

Our team of scientists will produce and commercialize products derived from cannabis-based botanical extracts. Even today, new uses for cannabinoids are consistently discovered. For example, scientists recently found that topical cannabinoid-based preparations can be effective against MRSI, the deadly antibiotic-resistant flesh-eating disease. Other topical applications, which are largely non-psychoactive, would target localized pain, such as arthritis and burns, as well as neuropathic pain, for which there are few effective treatments.

In 2001, an article published in the Canadian Medical Association Journal revealed that, based on self-identified needs, it is estimated that 2% (or 400,000) of Canadian adults were already utilizing cannabinoids for medical purposes. With ever increasing use and scientific support for cannabinoid medicines occurring in the US and around the world, we are looking at a new multi-billion dollar industry that will play a dramatic role that will impact human health on a global scale.


CANNABINOIDS OVERVIEW


Cannabis sativa is one of the most widely used plants for both recreational and medicinal purposes. To date a total of 525 natural constituents covering several chemical classes have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, tetrahydrocannabinol commonly referred to as THC.

The most common natural plant cannabinoids (phytocannabinoids) are: THC, cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN). Several of the identified cannabinoids are both chemically and pharmacologically poorly characterized; however, the pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis.

Cannabinoids were first discovered in the 1940s, when CBD and CBN were identified. THC was not identified until 1964, but by that time cannabinoids had been removed from the pharmacopeiae of most countries, making further research on the plant difficult.

There are three general types of cannabinoids:

  1. Phytocannabinoids, that occur uniquely in the cannabis plant.
  2. Endogenous cannabinoids produced naturally in many animal species including humans.
  3. Synthetic cannabinoids compounds produced in a laboratory. Forms of synthetic THC are available by prescription in a number of countries, including the US. In the US, marketed as Marinol®.

Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids, are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin that is produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.


ENDOCANNABINOID SYSTEM


The endocannabinoid system refers to a group of neuromodulators and receptors involved in a variety of physiological processes including appetite, pain sensation, mood, and memory. The system is named for endocannabinoids, the endogenous lipids that bind cannabinoid receptors.

CB1 receptors are found throughout the body and are the most prevalent neurotransmitter system in the brain, specifically in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems.

CB2 receptors are found most exclusively in the immune system, with the greatest density in the spleen. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis. CB2 receptors appear in any tissue when there is pathology.

Science increasingly recognizes the role that endo-cannabinoids play in major life functions in the human body. Cannabinoids act as a bio regulatory mechanism, which explains why they have been recommended as a treatment for many diseases and ailments in anecdotal reports and scientific literature. Common prescribed ailments include: Pain, arthritic conditions, migraine headaches, anxiety, epileptic seizures, insomnia, loss of appetite, GERD (chronic heartburn), nausea, glaucoma, AIDS wasting syndrome, depression, bipolar disorder (particularly depression-manic-normal), multiple sclerosis, menstrual cramps, Parkinson’s, trigeminal neuralgia (tic douloureux), high blood pressure, irritable bowel syndrome, and bladder incontinence.

Cannabinoids have been used medicinally for thousands of years in China, India, and the Middle East. Of course, most traditional medicines were plant-based, but until recently no one knew how or why they worked. Though cannabinoids are a very old form of medication, we are inspired by this “folk medicine,” whose efficacy modern science now routinely verifies, and we are capable of creating systematic and effective use of cannabinoid therapies.

While cannabinoids were widely used in the West during the 19th century, the technology was lacking to detect and understand its active ingredients, to standardize dosages of those ingredients, and to effectively deliver those ingredients, owing largely to cannabinoids’ non-water-solubility. Consequently, it became less widely used in the early 20th century and was eventually renamed “marijuana”. It was gradually removed from the pharmacopeiae of most advanced countries; and research was discouraged.

No regulatory authority has examined or approved any of the information set out in this website or any other paper. No such action has been or will be taken under the laws, regulatory requirements or rules of any jurisdiction. The publication, distribution, or dissemination of this or this website or any other paper does not imply that the applicable laws, regulatory requirements, or rules have been complied with. The Cannabis Science platform is under development and is subject to further changes, updates, and adjustments prior to its launch. Such changes may result in unexpected and unforeseen effects on its projected appeal to users, possibly due to the failure to meet users preconceived expectations based on this or any other website or any other paper, and hence, impact its success.

Telegram
WhatsApp